Bibliometric Analysis of The Global Research Trends on The Application of Tamoxifen in The Treatment of Breast Cancer Over The Past 50 Years.

GLOBOCAN 2022 reported that breast cancer is a primary contributor to the incidence and mortality rates of cancer in women. The very high and low Human Development Index (HDI) tiers are the primary contributors to the highest incidence and mortality rates, respectively. This study aimed to provide a comprehensive landscape overview of trends, dynamics, and research hot spots on the application of tamoxifen in treating breast cancer over the past 50 years. We retrieved data from the Scopus database, spanning from 1973 to 2022. We utilised Microsoft Excel, Harzing's Publish or Perish, and VOSviewer to perform exhaustive analyses, including the publication trend, co-authorship, co-citation, co-occurrence of authors, organisations, countries, and keywords. A total of 3,721 publications fit the inclusion and exclusion criteria. Jordan VC was the most prominent author, making substantial contributions to the research topic. Erasmus MC was the most prolific organisation, while the Swiss Group for Clinical Cancer Research exhibited the most robust international collaboration. The United States and the United Kingdom consistently have the highest publication, TLS, and h- and g-indices. Using keyword co-occurrence analysis, we identify adjuvant endocrine therapy, postmenopausal, EGFR, HER2, and autophagy as research hot spots. For the past five decades, the research output of the application of tamoxifen in breast cancer treatment has exhibited an upward trend. This endeavour provides a crucial reference for researchers to direct greater attention toward research hot spots in the hope that it will improve breast cancer patients' treatments and, consequently, increase their survival rate.